ArticleaBIOTECH2020
Positional effects on efficiency of CRISPR/Cas9-based transcriptional activation in rice plants.
Article in aBIOTECH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Research progress and applications of gene activation editing technology in crops.Frontiers in plant science · 2026Review
- Transgene-Killer-CRISPR version 2 (TKC2) eliminates occasional transgene escape by coupling with a RUBY reporter.Plant biotechnology journal · 2025Article
- CRISPR/Cas genome editing in soybean: challenges and new insights to overcome existing bottlenecks.Journal of advanced research · 2025Review
- Unlocking Nature's Shield: The Promising Potential of CRISPRa in Amplifying Antimicrobial Peptide Expression in Common Bean (ACS omega · 2025Article
- Enhancement of Dendrobine Production by CRISPR/Act3.0-Mediated Transcriptional Activation of Multiple Endogenous Genes inInternational journal of molecular sciences · 2025Article
- How Helpful May Be a CRISPR/Cas-Based System for Food Traceability?Foods (Basel, Switzerland) · 2024Review
- Genomic approaches to enhance adaptive plasticity to cope with soil constraints amidst climate change in wheat.The plant genome · 2024Review
- CRISPR-Combo-mediated orthogonal genome editing and transcriptional activation for plant breeding.Nature protocols · 2023Review
- Applications of CRISPR/Cas genome editing in economically important fruit crops: recent advances and future directions.Molecular horticulture · 2023Review
- Bioprospecting microbes and enzymes for the production of pterocarpans and coumestans.Frontiers in bioengineering and biotechnology · 2023Review
- CRISPR-Cereal: a guide RNA design tool integrating regulome and genomic variation for wheat, maize and rice.Plant biotechnology journal · 2021Article
- CRISPR-Act3.0 for highly efficient multiplexed gene activation in plants.Nature plants · 2021Article
- Multiplex Genome-Editing Technologies for Revolutionizing Plant Biology and Crop Improvement.Frontiers in plant science · 2021Review
- CRISPR-Cas Activators for Engineering Gene Expression in Higher Eukaryotes.The CRISPR journal · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nuclease-dead Cas9 (dCas9) has been reprogrammed for transcriptional activation by fusing dCas9 to a transcriptional activation domain. In the presence of a guide RNA (gRNA), the dCas9 fusions specifically bind to regions of a promoter to activate transcription. Significant amount of effort has been directed toward the identification and optimization of the fusions of dCas9-activation domain, but very little is known about the impact of gRNA target positions within a promoter in plants on transcriptional activation efficiency. The dCas9-6TAL-VP128 system (dCas9-TV) has been optimized to activate transcription in plants. Here we use the dCas9-TV to activate transcription of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.